RBC Capital analyst Frank Morgan maintained a Buy rating on Acadia Healthcare (NASDAQ:ACHC) Company Inc. on Thursday, setting a price target of $74, which is approximately 9.14% above the present share price of $67.8.
Morgan expects Acadia Healthcare Company Inc. to post earnings per share (EPS) of $0.11 for the second quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Acadia Healthcare, with an average price target of $68.
The analysts price targets range from a high of $75 to a low of $60.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $551.2 million and a net profit of $87.61 million. The company's market cap is $6.08 billion.
According to TipRanks.com, RBC Capital analyst Frank Morgan is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 23.5% and a 68.26% success rate.
Acadia Healthcare Co., Inc. engages in the provision of behavioral healthcare services. It operates through the following segments: United States (U.S.) Facilities and the United Kingdom (U.K.) Facilities. The U.S. Facilities segment classified in the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; residential treatment centers; and outpatient community-based services. The U.K. Facilities segment provides inpatient services through facilities, including mental health hospitals, clinics, care homes, schools, colleges, and children's homes. The company was founded in January 2005 and is headquartered in Franklin, TN.